Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISN - Sight Resources -- Ignore unavailable to you. Want to Upgrade?

To: straight life who wrote (66)	6/7/1999 6:11:00 PM
From: Ram Seetharaman	Read Replies (1) \| Respond to of 103

Ackerman of Fahnstock is one! After his recommendation couple of years ago, stock went down as low as $ 1+. So his word isn't worth much, since he was wrong! Now the new President Sullivan has turned the company around and VISN is looking healthy. Sullivan himself bought a year's worth of his salary in VISN stock, when it was trading in the low 2s and 3s. As of 6-3-99 VISN rating seems to have dissipated to a "moderate buy" rating from a "strong buy" couple of months ago! Today's volume of 200000+ was healthy and IMHO $ 5+ is not far away! Once it becomes marginable security for a few months and the earnings improve even the teens are possible!

To: straight life who wrote (66)	8/18/1999 6:25:00 PM
From: Ram Seetharaman	Read Replies (1) \| Respond to of 103

Long time no news on VISN! 08/18 10:18 SpectraSCIENCE Appoints Executive Vice President <SPSI.OB> SpectraSCIENCE Appoints Executive Vice President MINNEAPOLIS--(BUSINESS WIRE)--Aug. 18, 1999--SpectraSCIENCE, Inc. (OTC:SPSI) announced today that Mr. Stephen M. Blinn has been appointed as its Executive Vice President. Mr. Blinn's duties will focus primarily on sales, marketing and new business development. Mr. Blinn has extensive experience with the commercialization of medical devices that began in the Medical Products Division of 3M Company in the 1970's. During his career he has been involved with infection control systems, cardiac pacemakers, ambulatory infusion devices and, for the past 12 years, medical lasers. From 1998 until July of 1999 Mr. Blinn served as President/CEO for SilverPlatter Education, Inc., an electronic medical publishing company. SilverPlatter was a turn-around situation that Mr. Blinn brought to profitability and successfully sold to HealthStream Corporation; a Nashville, Tennessee based company specializing in content aggregation of medical information for the Internet. In 1993 Mr. Blinn co-founded Sight Resource Corporation (NASDAQ: VISN) and served as its Chief Operating Officer until 1998. He continues to serve on its board of directors. While at Sight Resource he was instrumental in growing the company into the thirteenth largest primary eye care provider in the United States with over $50 million in annual revenue. From 1987 to 1993 Mr. Blinn served as Vice President of Sales and Marketing and then as Executive Vice President for Summit Technology (NASDAQ: BEAM), a worldwide leader in Laser Vision Correction utilizing excimer lasers. While at Summit he was directly responsible for opening 33 international markets and growing annual sales from $0 to $35 million prior to FDA approval. Chet Sievert, President and CEO for SpectraSCIENCE, stated: "Steve's broad experience in the medical industry is extremely valuable to us as we move toward FDA approval for our Optical Biopsy(TM) System. His in-depth familiarity with medical device start-up companies and his knowledge regarding capital markets and new business development are particularly well suited to the immediate and future needs of the company. I am extremely pleased to welcome Steve on board and look forward to working with him during these exciting times for SpectraSCIENCE." Based in Minneapolis, SpectraSCIENCE, Inc. (www.spectrascience.com) develops innovative spectrophotometry systems capable of determining whether tissue is normal, potentially cancerous or cancerous. This news release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. Additional risks that may affect the Company's future performance are detailed in Exhibit 99 to the Company's Quarterly Report on Form 10-QSB for the quarter ended March 31, 1999. --30--dp/ms* CONTACT: SpectraSCIENCE, Minneapolis Marie Johnson 612-509-9999, extension 203. Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com (c) 1998 Business Wire